Back to Search
Start Over
Beneficial effects of angiotensin-(1-7) against deoxycorticosterone acetate-induced diastolic dysfunction occur independently of changes in blood pressure.
- Source :
-
Hypertension (Dallas, Tex. : 1979) [Hypertension] 2015 Aug; Vol. 66 (2), pp. 389-95. Date of Electronic Publication: 2015 Jun 15. - Publication Year :
- 2015
-
Abstract
- Mineralocorticoids have been implicated in the pathogenesis of diastolic heart failure. On the contrary, angiotensin (Ang)-(1-7) has emerged as a potential strategy for treatment of cardiac dysfunction induced by excessive mineralocorticoid receptor activation. A critical question about the cardioprotective effect of Ang-(1-7) in hypertensive models is its dependence on blood pressure (BP) reduction. Here, we addressed this question by investigating the mechanisms involved in Ang-(1-7) cardioprotection against mineralocorticoid receptor activation. Sprague-Dawley (SD) and transgenic (TG) rats that overexpress an Ang-(1-7) producing fusion protein (TG(A1-7)3292) were treated with deoxycorticosterone acetate (DOCA) for 6 weeks. After treatment, SD rats became hypertensive and developed ventricular hypertrophy. These parameters were attenuated in TG-DOCA. SD-DOCA rats developed diastolic dysfunction which was associated at the cellular level with reduced Ca(2+) transient. Oppositely, TG-DOCA myocytes presented enhanced Ca(2+) transient. Moreover, higher extracellular signal-regulated kinase phosphorylation, type 1 phosphatase, and protein kinase Cα levels were found in SD-DOCA cells. In vivo, pressor effects of DOCA can contribute to the diastolic dysfunction, raising the question of whether protection in TG was a consequence of reduced BP. To address this issue, BP in SD-DOCA was kept at TG-DOCA level by giving hydralazine or by reducing the DOCA amount given to rats (Low-DOCA). Under similar BP, diastolic dysfunction and molecular changes were still evident in DOCA-hydralazine and SD-low-DOCA, but not in TG-DOCA. In conclusion, Ang-(1-7) protective signaling against DOCA-induced diastolic dysfunction occurs independently of BP attenuation and is mediated by the activation of pathways involved in Ca(2+) handling, hypertrophy, and survival.<br /> (© 2015 American Heart Association, Inc.)
- Subjects :
- Angiotensin I pharmacology
Animals
Blood Pressure drug effects
Calcium physiology
Calcium Signaling drug effects
Calcium Signaling physiology
Disease Models, Animal
Dose-Response Relationship, Drug
Heart Failure, Diastolic physiopathology
Hydralazine pharmacology
Hypertension physiopathology
Male
Peptide Fragments pharmacology
Rats
Rats, Sprague-Dawley
Rats, Transgenic
Angiotensin I therapeutic use
Blood Pressure physiology
Desoxycorticosterone Acetate adverse effects
Heart Failure, Diastolic chemically induced
Heart Failure, Diastolic prevention & control
Peptide Fragments therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4563
- Volume :
- 66
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Hypertension (Dallas, Tex. : 1979)
- Publication Type :
- Academic Journal
- Accession number :
- 26077567
- Full Text :
- https://doi.org/10.1161/HYPERTENSIONAHA.114.04893